This is a trial for those with a confirmed diagnosis of Philadelphia chromosome negative MPN neoplasm based on WHO classification including Chronic Neutrophilic Leukemia (CNL), atypical Chronic Myeloid Leukemia (aCML), Chronic Myelomonocytic Leukemia (CMML), Myelodysplastic/myeloproliferative neoplasm unclassifiable, accelerated phase myelofibrosis and MPN unclassifiable (defined as peripheral and or bone marrow blasts of 10-19%). Patients with early stages of Polycythemia Vera or Essential Thrombocytosis will be excluded from the study.
SGI-110 has demonstrated safety and efficacy in patients with MDS, Acute Myeloid Leukemia (AML), and CMML. Based on this data, it is believed that SGI-110 will result in similar affects in this patient set.
The study drug works by controlling gene expression and is hypothesized to be safer than alternatives.
Duration of treatment is dependent on individual response and no experience of unacceptable side affects. Patients will be in follow-up monthly for six months.
SGI-110 is administered subcutaneously on the first 5 days of every month.